证券代码：603658 证券简称：安图生物 公告编号：2024-081 郑州安图生物工程股份有限公司 第五届监事会第一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 监事会会议召开情况 郑州安图生物工程股份有限公司（以下简称"公司"）第五届监事会第一次会 议于2024年10月28日在公司会议室以现场方式召开，全体监事一致推举公司监事 韩明明先生主持本次会议，并同意豁免会议通知时间要求。会议应参加监事3名， 实际参加监事3名。会议的召集和召开程序符合《公司法》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，以记名投票表决方式一致通过以下议案： 审议通过《关于选举公司第五届监事会主席的议案》 特此公告。 郑州安图生物工程股份有限公司监事会 2024年10月28日 全体监事均亲自出席本次监事会。 无监事对本次监事会议案投反对/弃权票。 本次监事会全部议案均获通过。 根据《中华人民共和国公司法》《公司章程 ...

郑州安图生物工程股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603658 证券简称：安图生物 公告编号：2024-079 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 10 月 28 日 (二)股东大会召开的地点：公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 210 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 415,304,374 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 72.6263 | 注：截至本次股东大会股权登记日，公司回购专用账户中共有公司股份 9,174,352 股，根据 《上市公司股份回购规则》等相关规定，该部分股份不享有股东大会表决权，本次股东大会 计算相关比例时已扣除上述已回购股份。 (四)表决方式是否符 ...

证券代码：603658 证券简称：安图生物 公告编号：2024-083 郑州安图生物工程股份有限公司 关于公司高级管理人员薪酬方案的公告 一、适用对象 公司第五届高级管理人员（含兼任董事的高级管理人员）。 二、适用期限 自公司董事会审议通过之日起生效实施，至新的薪酬方案通过日止。 2. 效益激励=效益薪酬×指标完成比例×利润指标完成系数×销售任务完成系 数。其中考核指标根据个人职责制定单独考核方案，年度结束后按照相关考核方 案计算确定当年度发放额，利润指标完成系数及销售任务完成系数结合公司年度 完成情况进行计算。 四、其他说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年10月28日召开 第五届董事会第一次会议，根据《公司法》及《公司章程》等有关规定，审议通 过了《关于公司高级管理人员薪酬方案的议案》。该议案已经公司董事会薪酬与 考核委员会审议通过，并同意提交公司董事会审议。现将具体情况公告如下： 三、薪酬结构 公司高级管理人员按其在公司任职的管理岗位领取薪酬，采 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Views - The company reported a revenue of 3.38 billion yuan for Q3 2024, a year-on-year increase of 3.38%, while the net profit attributable to shareholders decreased by 5.18% to 337 million yuan [1]. - The company is expected to benefit from the gradual realization of domestic substitution in the chemical luminescence industry, as new procurement projects are anticipated to commence [1]. - High investment in R&D continues, with a focus on new reagent projects and instrument platform development, enhancing the company's competitive strength [1]. - The company has received multiple medical device registrations recently, which will enrich its product offerings and improve overall competitiveness [1]. - The short-term performance is impacted by factors such as DRG implementation and industry restructuring, leading to a downward revision of net profit forecasts for 2024-2026 [1]. Financial Summary - For the first nine months of 2024, the company achieved a revenue of 3.38 billion yuan (+4.24%) and a net profit of 956 million yuan (+6.13%) [1]. - The projected revenues for 2024, 2025, and 2026 are 45.42 billion yuan, 54.68 billion yuan, and 65.67 billion yuan, respectively, with growth rates of 2.20%, 20.40%, and 20.09% [3]. - The net profit forecasts for the same years are 1.32 billion yuan, 1.60 billion yuan, and 1.95 billion yuan, with growth rates of 8.77%, 20.98%, and 21.80% [3]. - The company's EPS for 2024, 2025, and 2026 is projected to be 2.28 yuan, 2.76 yuan, and 3.36 yuan, respectively [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing stable performance amidst multiple pressures, with a focus on potential turning points following policy clarifications [1] - The company has shown resilience in its conventional business operations, with expectations for accelerated growth as various policies are fully implemented [1] - The report highlights the company's ongoing investment in research and development, which is expected to drive long-term growth [1] Financial Performance Summary - **Revenue Forecasts**: - 2022A: 4,442 million - 2023A: 4,444 million - 2024E: 4,630 million - 2025E: 5,359 million - 2026E: 6,415 million - Year-on-year growth rates: 2023A: 0%, 2024E: 4%, 2025E: 16%, 2026E: 20% [1] - **Net Profit Forecasts**: - 2022A: 1,167 million - 2023A: 1,217 million - 2024E: 1,330 million - 2025E: 1,545 million - 2026E: 1,872 million - Year-on-year growth rates: 2023A: 4%, 2024E: 9%, 2025E: 16%, 2026E: 21% [1] - **Earnings Per Share (EPS)**: - 2022A: 2.01 - 2023A: 2.10 - 2024E: 2.29 - 2025E: 2.66 - 2026E: 3.22 [1] - **Cash Flow and Profitability**: - Cash flow per share: 2023A: 2.53, 2024E: 3.32, 2025E: 3.06, 2026E: 3.32 [1] - Return on equity (ROE): 2023A: 14%, 2024E: 13%, 2025E: 14%, 2026E: 14% [1] - **Valuation Ratios**: - Price-to-earnings (P/E) ratio: 2023A: 21.3, 2024E: 19.5, 2025E: 16.8, 2026E: 13.9 [1] - Price-to-book (P/B) ratio: 2023A: 3.0, 2024E: 2.7, 2025E: 2.3, 2026E: 2.0 [1] Business Overview - The company reported a year-on-year revenue growth of 6.13% for the first three quarters of 2024, with a net profit of 3.37 billion, reflecting a decline of 5.18% year-on-year but a 14.01% increase quarter-on-quarter [1] - The company is expected to benefit from the gradual release of pressure from regulatory policies, with a focus on enhancing its research and development capabilities [1] - The report indicates that the company’s self-developed products and increasing customer demand are expected to support growth in the chemical luminescence business, while the biochemical segment may face short-term pressure due to pricing adjustments [1]

Investment Rating - The report maintains a "Recommended" rating for the company [5] Core Views - The company's revenue continues to show a steady growth trend, aligning with market expectations. In the first three quarters of 2024, the company achieved an operating income of 3.38 billion yuan, a year-on-year increase of 4.24%, and a net profit attributable to shareholders of 956 million yuan, up 6.13% year-on-year. In Q3 alone, the operating income was 1.173 billion yuan, reflecting a year-on-year growth of 3.38%, while the net profit attributable to shareholders decreased by 5.18% [2][3] - The company is focusing on its core business and actively expanding its market presence despite facing multiple pressures in the domestic market, such as medical anti-corruption and the expansion of DRGs execution. The revenue growth rate in Q3 remained consistent with the trend observed in the first half of the year [3] - The company has a comprehensive layout in various testing fields, including immunology, microbiology, molecular diagnostics, biochemistry, and mass spectrometry, which provides significant development space. The company has established core competitive advantages in technology innovation, manufacturing quality, resource integration, and customer service over more than two decades [3] - The company successfully launched a series of self-antibody testing products in 2024, with 33 products expected to be launched in the first phase, enhancing product competitiveness. Additionally, the company introduced the high-throughput fully automated biochemical analyzer B2000 series, further enriching its biochemical testing product line [3] Financial Summary - For the fiscal years 2024 to 2026, the company is projected to achieve an EPS of 2.40 yuan, 2.81 yuan, and 3.49 yuan respectively, indicating a positive long-term growth outlook [5] - The company's operating income is expected to grow from 4.444 billion yuan in 2023 to 6.586 billion yuan in 2026, with a compound annual growth rate (CAGR) of approximately 18.7% [4][6] - The net profit is projected to increase from 1.217 billion yuan in 2023 to 2.031 billion yuan in 2026, reflecting a strong growth trajectory [4][6] - The gross margin is expected to remain stable around 65% over the forecast period, with a slight increase to 66% by 2026 [4][8]

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,172,931,144.85, representing a year-over-year increase of 3.38%[2] - The net profit attributable to shareholders for Q3 2024 was ¥336,661,203.63, showing a decrease of 5.18% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥331,565,655.02, down by 3.99% year-over-year[2] - The basic earnings per share for Q3 2024 was ¥0.59, a decrease of 3.28% compared to the same period last year[4] - Total operating revenue for the first three quarters of 2024 reached ¥3,380,035,059.48, an increase of 4.25% compared to ¥3,242,497,407.54 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was ¥969,432,633.28, compared to ¥915,410,745.17 in 2023, indicating a growth of 5.90%[17] - The net profit attributable to the parent company for Q3 2024 was ¥956,174,546.82, an increase from ¥900,920,385.63 in Q3 2023, representing a growth of approximately 6.1%[18] - The total comprehensive income for Q3 2024 reached ¥969,294,287.00, compared to ¥915,998,287.10 in Q3 2023, indicating an increase of about 5.8%[18] - The basic and diluted earnings per share for Q3 2024 were both ¥1.65, up from ¥1.55 in Q3 2023, reflecting a growth of 6.5%[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,389,469,846.36, reflecting a decrease of 1.42% from the end of the previous year[4] - The equity attributable to shareholders at the end of the reporting period was ¥8,402,371,569.16, down by 1.56% compared to the end of the previous year[4] - Total assets as of the end of the third quarter of 2024 were ¥11,389,469,846.36, slightly down from ¥11,554,058,269.37 at the end of the previous year[14] - Total liabilities as of the end of the third quarter of 2024 were ¥2,903,356,026.00, compared to ¥2,887,726,931.49 in the same period last year, showing an increase of 0.89%[14] - Non-current assets totaled ¥5,254,767,410.80, up from ¥4,941,037,667.56 in the previous year, indicating a growth of 6.35%[14] - The company's equity attributable to shareholders was ¥8,402,371,569.16, a decrease from ¥8,535,461,518.03 in the previous year[14] - The company reported a decrease in short-term borrowings to ¥253,700,475.15 from ¥343,300,545.69, a reduction of 26.16%[14] Cash Flow - The company reported a net cash flow from operating activities of ¥948,965,414.66 for the year-to-date, a slight decrease of 0.23% year-over-year[2] - Cash inflows from operating activities for the first three quarters of 2024 amounted to ¥3,754,808,838.97, compared to ¥3,608,645,364.91 in the same period of 2023, marking an increase of approximately 4.0%[19] - The net cash flow from operating activities for the first three quarters of 2024 was ¥948,965,414.66, slightly down from ¥951,113,025.41 in the first three quarters of 2023[19] - Cash outflows from investing activities totaled ¥2,400,651,358.70 in the first three quarters of 2024, compared to ¥1,599,897,102.58 in the same period of 2023, indicating a significant increase of approximately 50.1%[20] - The net cash flow from financing activities for the first three quarters of 2024 was -¥1,142,060,159.46, compared to -¥191,706,034.07 in the same period of 2023, showing a decline in cash flow[20] - The cash and cash equivalents at the end of Q3 2024 were ¥319,752,756.90, down from ¥442,045,146.47 at the end of Q3 2023, representing a decrease of about 27.7%[20] Shareholder Information - The company has a total of 32,634 common shareholders at the end of the reporting period[7] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 56.70% of the shares[7] - The controlling shareholder, Antu Industrial Group, increased its shareholding by 0.50% due to a reduction in total share capital[9] - As of the end of the reporting period, the company had repurchased 8,891,492 shares, accounting for 1.53% of the total share capital[9] - The company announced a share buyback plan, with Antu Industrial having already acquired 5,541,300 shares, representing 0.95% of the total share capital[10] Non-Recurring Gains and Losses - Non-recurring gains and losses for the current period totaled ¥5,095,548.61, with government subsidies contributing ¥11,086,646.32[5] Research and Development - Research and development expenses for the first three quarters of 2024 amounted to ¥511,265,272.32, an increase from ¥461,553,959.80 in the previous year, representing an increase of 10.75%[17] Inventory and Receivables - Accounts receivable increased to RMB 1,224,124,243.89 from RMB 1,153,256,246.40, reflecting a growth of approximately 6.2%[12] - Inventory rose to RMB 931,110,862.72, up from RMB 778,288,488.44, marking an increase of around 19.6%[12] Fixed Assets - The company reported a significant increase in fixed assets, which rose to RMB 3,015,555,885.87 from RMB 2,253,588,682.87, indicating a growth of about 33.8%[12] - The company's total non-current assets increased to RMB 4,192,000,000.00 from RMB 3,865,000,000.00, showing a growth of approximately 8.5%[12] - The company's long-term equity investments increased to RMB 13,434,149.16 from RMB 7,422,109.63, reflecting a growth of approximately 81.5%[12] Accounting Standards - The company did not apply new accounting standards or interpretations that would affect the financial statements for the year of first implementation[21]

证券代码：603658 证券简称：安图生物 公告编号：2024-078 2024年10月23日 鉴于郑州安图生物工程股份有限公司（以下简称"公司"）第四届监事会任期 即将届满，根据《公司法》《公司章程》等的有关规定，公司于2024年10月23 日召开第五届职工代表大会第一次会议，经职工代表现场表决，同意选举刘微女 士担任公司第五届监事会职工代表监事。 刘微女士将与公司2024年第三次临时股东大会选举产生的其他两名股东代 表监事共同组成公司第五届监事会，任期为自2024年第三次临时股东大会决议生 效之日起三年，与公司第五届监事会任期一致。 特此公告。 附：职工代表监事简历。 郑州安图生物工程股份有限公司监事会 郑州安图生物工程股份有限公司 关于职工代表监事换届选举的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 刘微女士，汉族，中国国籍，无境外居留权，1976年出生，本科学历，高级经济师。 1998年至2000年任天津渤海职业高等专科学校教师；2000年至2003年就职河南思达配网技术 有限公司，历任职员、综合办主任；20 ...

Autobio Diagnostics CO., Ltd. 安图生物 2024 年第三次临时股东大会会议材料 河南·郑州 二○二四年十月 郑州安图生物工程股份有限公司 Autobio Diagnostics CO., Ltd. 安图生物 2024 年第三次临时股东大会会议材料 郑州安图生物工程股份有限公司 2024 年第三次临时股东大会目录 一、程序文件 郑州安图生物工程股份有限公司 郑州安图生物工程股份有限公司 2024年第三次临时股东大会会议材料 （股票代码：603658） 二、提交股东大会审议的议案 1. 会议议程 2. 会议须知 1. 《关于第五届董事会董事薪酬方案的议案》 2. 《关于第五届监事会监事薪酬方案的议案》 3. 《关于修订〈公司章程〉条款的议案》 4.00 《关于公司董事会换届选举第五届非独立董事的议案》 4.01 苗拥军 4.02 张亚循 4.03 杨增利 4.04 吴学炜 4.05 付光宇 4.06 冯超姐 4.07 张瑞峰 5.00 《关于公司董事会换届选举第五届独立董事的议案》 5.01 顾军 5.02 祁园明 5.03 申香华 5.04 袁华刚 6.00 《关于公司监事会换届选 ...

证券代码：603658 证券简称：安图生物 公告编号：2024-075 郑州安图生物工程股份有限公司 关于 2024 年第三次临时股东大会增加临时提案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2024 年第三次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 603658 | 安图生物 | 2024/10/18 | 二、 增加临时提案的情况说明 公司已于 2024 年 10 月 12 日公告了股东大会召开通知，单独或者合计持有 56.70%股份的股东郑州安图实业集团股份有限公司，在 2024 年 10 月 16 日提出 临时提案并书面提交公司董事会。公司董事会按照《上市公司股东大会规则》有 2. 股东大会召开日期：2024 年 10 月 28 日 3. 股权登记日 四、 增加临时提案后股东大会的有关情况。 (一) 现场会议召开的日期、时间和地点 召开日期时间：2024 ...